~~<i id='C2D5A74E0F'><strike id='C2D5A74E0F'><tt id='C2D5A74E0F'><pre id='C2D5A74E0F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：entertainment 2025-09-06 20:45:47 - browse：13633

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Food makers to regulators: Ultra

hotspot

explore

entertainment

focus

AdobePatientsoftenasktwoquestionsabouteverymedicaltreatment:Willithelpme?Willithurtme?TheFoodandDrug

WSS

IRA could hurt research into orphan drugs for rare diseases

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

New weight loss drugs vying to be the next Wegovy or Mounjaro

IRA could hurt research into orphan drugs for rare diseases

Regeneron agrees to White House price limits on anti

Walmart eyes Medicare Advantage provider ChenMed

hotspot

leisure time

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Food makers tried to stack nutrition panel with preferred experts

Moonlake's readout produced a cash windfall. Risks remain

How housing is health care on Long Island

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How to make the FDA’s new prescription one

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Drug repurposing or repositioning? The language matters

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

hotspot

Regeneron agrees to White House price limits on anti

How housing is health care on Long Island

How housing is health care on Long Island

Hospitals consider fixing cancer drug shortages on their own

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

White House touts steps to stem shortages of cancer treatments

explore

entertainment

focus

focus